PH12021550424A1 - Method for producing an antitumoral arenavirus as well as arenavirus mutants - Google Patents

Method for producing an antitumoral arenavirus as well as arenavirus mutants

Info

Publication number
PH12021550424A1
PH12021550424A1 PH12021550424A PH12021550424A PH12021550424A1 PH 12021550424 A1 PH12021550424 A1 PH 12021550424A1 PH 12021550424 A PH12021550424 A PH 12021550424A PH 12021550424 A PH12021550424 A PH 12021550424A PH 12021550424 A1 PH12021550424 A1 PH 12021550424A1
Authority
PH
Philippines
Prior art keywords
arenavirus
antitumoral
mutants
producing
well
Prior art date
Application number
PH12021550424A
Other languages
English (en)
Inventor
Karl Lang
Cornelia Hardt
Michael Bergerhausen
Hilal Bhat
Original Assignee
Abalos Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abalos Therapeutics Gmbh filed Critical Abalos Therapeutics Gmbh
Publication of PH12021550424A1 publication Critical patent/PH12021550424A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10051—Methods of production or purification of viral material
    • C12N2760/10052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PH12021550424A 2018-09-12 2021-03-01 Method for producing an antitumoral arenavirus as well as arenavirus mutants PH12021550424A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102018215551.8A DE102018215551A1 (de) 2018-09-12 2018-09-12 Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten
PCT/EP2019/074307 WO2020053324A1 (en) 2018-09-12 2019-09-12 Method for producing an antitumoral arenavirus as well as arenavirus mutants

Publications (1)

Publication Number Publication Date
PH12021550424A1 true PH12021550424A1 (en) 2021-09-20

Family

ID=68138008

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021550424A PH12021550424A1 (en) 2018-09-12 2021-03-01 Method for producing an antitumoral arenavirus as well as arenavirus mutants

Country Status (18)

Country Link
US (2) US12129281B2 (cg-RX-API-DMAC7.html)
EP (2) EP4019533A1 (cg-RX-API-DMAC7.html)
JP (1) JP7583448B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210057782A (cg-RX-API-DMAC7.html)
CN (2) CN120158432A (cg-RX-API-DMAC7.html)
AU (1) AU2019340845B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004451A2 (cg-RX-API-DMAC7.html)
CA (1) CA3111305A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000592A1 (cg-RX-API-DMAC7.html)
DE (1) DE102018215551A1 (cg-RX-API-DMAC7.html)
DK (1) DK3694868T3 (cg-RX-API-DMAC7.html)
ES (1) ES2908854T3 (cg-RX-API-DMAC7.html)
IL (1) IL281299B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021002937A (cg-RX-API-DMAC7.html)
PH (1) PH12021550424A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101970UA (cg-RX-API-DMAC7.html)
WO (1) WO2020053324A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202101833B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022180203A1 (en) 2021-02-26 2022-09-01 Abalos Therapeutics Gmbh New virus particles for therapeutic purposes
IL326615A (en) * 2023-08-31 2026-04-01 Abalos Therapeutics Gmbh Virus particles with improved entry into tumor cells
CN117867030A (zh) * 2024-01-15 2024-04-12 苏州健雄职业技术学院 小鼠肺癌细胞系cmt167荧光素酶稳转细胞株的构建与应用
CN122357626A (zh) * 2025-10-30 2026-07-10 山东第一医科大学(山东省医学科学院) 一种抑制塔姆德病毒感染的方法及tcp1抑制剂的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004034461B4 (de) 2004-07-16 2008-02-07 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren
CN103993012B (zh) 2007-12-27 2023-01-10 苏黎士大学 复制缺陷型沙粒病毒载体
KR20110074563A (ko) 2008-09-24 2011-06-30 메디뮨 엘엘씨 바이러스의 정제 방법
CN102439146A (zh) 2009-03-23 2012-05-02 巴斯德研究院 适合将免疫原性分子递送到细胞中的突变CyaA多肽及多肽衍生物
WO2012093340A2 (en) * 2011-01-07 2012-07-12 Bioscience Slovakia Viral diagnostics
JP6162818B2 (ja) * 2012-12-12 2017-07-12 チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド 脳癌の治療のための組成物及び方法
DE102015207036A1 (de) * 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
CN110167586B (zh) * 2016-11-04 2024-01-30 霍欧奇帕生物科技有限公司 作为癌症疫苗的复制-缺陷型沙粒病毒颗粒和三-节段沙粒病毒颗粒

Also Published As

Publication number Publication date
MX2021002937A (es) 2021-07-16
ZA202101833B (en) 2022-10-26
SG11202101970UA (en) 2021-03-30
WO2020053324A1 (en) 2020-03-19
EP3694868A1 (en) 2020-08-19
ES2908854T3 (es) 2022-05-04
US12129281B2 (en) 2024-10-29
DE102018215551A1 (de) 2020-03-12
JP7583448B2 (ja) 2024-11-14
EP3694868B1 (en) 2021-11-03
NZ774584A (en) 2024-09-27
IL281299B2 (en) 2025-07-01
CN112996802A (zh) 2021-06-18
CN120158432A (zh) 2025-06-17
IL281299B1 (en) 2025-03-01
US20250122244A1 (en) 2025-04-17
EP4019533A1 (en) 2022-06-29
CN112996802B (zh) 2025-03-11
CL2021000592A1 (es) 2021-09-10
KR20210057782A (ko) 2021-05-21
US20220033445A1 (en) 2022-02-03
JP2022500054A (ja) 2022-01-04
IL281299A (en) 2021-04-29
AU2019340845B2 (en) 2026-01-29
CA3111305A1 (en) 2020-03-19
BR112021004451A2 (pt) 2021-06-01
DK3694868T3 (da) 2022-02-07
AU2019340845A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
CL2021000592A1 (es) Método para producir un arenavirus antitumoral así como mutantes de arenavirus
MX2025002980A (es) Compuestos de anillo fusionado
MX2026002469A (es) Nuevas moleculas de acido nucleico artificiales
MX2020009326A (es) Anticuerpos anti-claudina 18.2 y usos de los mismos.
MY190625A (en) Anti-vegf protein compositions and methods for producing the same
WO2017191274A3 (en) Rna encoding a therapeutic protein
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
MY205512A (en) Arginase inhibitors
EP4667565A3 (en) Methods and compositions for the treatment of fabry disease
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
BR112017005987A2 (pt) ponta ultrassônica para instrumento ultrassônico e método de tratamento dentário com a referida ponta ultrassônica.
WO2018132821A3 (en) Elastomeric proteins
ZA202110285B (en) Antibodies and methods of use
WO2019118512A3 (en) Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis
PH12021551223A1 (en) Decarboxylase inhibitors for treating parkinson`s disease
PH12021500028A1 (en) Pseudofab-based multispecific binding proteins
MX2023012672A (es) Nuevo anticuerpo anti-vista estable.
WO2024023262A3 (en) Nucleic acid compounds
WO2022236276A3 (en) Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof
WO2021158755A3 (en) Leptospiral proteins and uses thereof
WO2020049598A3 (en) Apalutamide polymorphs
WO2019147979A3 (en) Peptides for angiogenic therapy
MX2020013684A (es) Formulaciones/composiciones que comprenden ibrutinib.
MX2024001304A (es) Composiciones y metodos para anticuerpos anti-pacap.
ZA202100231B (en) Non-viable bifidobacterium bifidum bacteria and uses thereof